Biologics Battle Over Billions of Dollars
Fight Fueled by FTC Report That Says 12-Year Exclusivity Unnecessary
Roll Call Staff
Lobbyists who want Congress to approve a swift pathway to generic versions of biotech drugs say the Federal Trade Commission last week handed their side a boost just as Congress wades into the health care reform debate.
Forget your password? Click here or
Call 202-824-6800
Subscribe to Print and/or Online
Click Here
Hill Users have Free access,
click Here to register.
Schumer Advocates for Many on Panel
Nov. 16, 12 a.m.
As Senate Majority Leader, Lyndon Johnson once said of the Joint Economic Committee, Its as useless as tits on a bull. But as that panels chairman during the 110th Congress, Sen. Charles Schumer (D-N.Y.) seized the opportunity to elevate the traditionally low-profile post to the forefront of shaping policy. Read Full Article










